News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
43.35 ^USD	-7.45%		-1.92%	+18.77%

06:49pm	Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	MT
05:24pm	SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	05:49pm	MT
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	04:24pm	MT
Transcript : SpringWorks Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024	01:30pm
SpringWorks Therapeutics: Q1 Earnings Snapshot	11:45am	AQ
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	11:39am	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11:32am	CI
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	11:30am	GL
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	04-24	GL
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	04-18	GL
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	03-12
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	03-06	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	03-06	MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	03-04	MT
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	03-04	GL
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	03-04	CI
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	02-29	GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	02-29	AQ
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	02-27	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
SpringWorks Therapeutics: Q4 Earnings Snapshot	02-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Summary

Filters